Board of Directors

Gautam Doshi, a Chartered Accountant with a Masters degree in Commerce, has been in professional practice for over 40 years. He advises various industrial groups & families and also serves as director on the boards of public listed and unlisted companies.

Mr. Doshi has more than 40 years of experience in wide range of areas covering Mergers and Acquisitions, Direct, Indirect and International Taxation, Transfer Pricing, Accounting and Corporate and Commercial Laws. He has been actively involved in conceptualizing and implementing a number of mergers and restructuring transactions both domestic and cross border, involving many of the top 20 listed companies on the BSE as also those forming part of FTSE 100.

A prolific speaker, Mr Doshi has addressed several seminars and conferences within and outside of India, and courses organized by the Institute of Chartered Accountants of India, International Fiscal Association, other professional bodies and Chambers of Commerce. He has served on the Councils of Western Region as also All India level of the Institute of Chartered Accountants of India which has the task of development and regulation of profession of accountancy in India. During his tenure on the Council, he served on several committees and contributed significantly to the work of Board of Studies which is responsible for education and system of training of students. He also served as Chairman of Committees on direct and indirect taxation.

Sanjay Asher is presently a Senior Partner with M/s. Crawford Bayley & Co., which is India’s oldest law firm, established in 1830.

Mr. Asher holds a Bachelor’s Degree in Commerce and a Bachelor’s Degree in Law from the University of Bombay. He has been a practicing Advocate since 1991, and was admitted as a Solicitor in the year 1993. He is also a qualified Chartered Accountant. 

He specialises in the fields of M&A, cross border M&A, joint ventures, private equity and capital markets. 

He has been a noted speaker at various seminars and conferences including those organised by Institute of Chartered Accountants of India and Institute of Company Secretaries of India. 

He has authored several national and international publications including a book on Companies Act, 2013 which was published by CCH, a Wolters Kluwer publication.

 Click here to view the Directorships in Indian companies.

Kirti Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company’s India Business has grown consistently, further increasing its market share. Previously, he has held various leadership roles across Business Development, Marketing, M&A, New Product Introduction, Project Management, IP and Litigation at Sun Pharma. He played a key role in driving Sun Pharma’s foray into specialty by securing rights for key products such as Illumya. Kirti Ganorkar led Sun Pharma’s entry into Japan and laid the initial groundwork for the Company’s entry into Europe. He supported US business with stewardship of several notable generic projects from concept to commercialisation. Kirti Ganorkar is a chemical engineer and MBA.

Click here to view the Directorships in Indian companies.

Aalok joined Sun in 2006 and has handled various roles in Marketing, R&D, Project Management, Purchase & Communications. In 2010, he headed Bangladesh and by 2014, he took over the Emerging Markets business, which is spread across 80 countries covering Africa, Middle East, APAC, Eastern Europe, CIS, and Latam. Subsequently, he also took charge of Global Generic R&D, Global Generic Business Development and API. He has done his undergraduate majoring in Cellular and Molecular Biology from the University of Michigan – Ann Arbor.

Click here to view the Directorships in Indian companies.

Rolf Hoffmann is a Strategic and results-orientated Executive who is highly respected for expertise in creating and optimizing commercial opportunities in all global markets. He has over 29 years of experience managing top 50 worldwide markets with full P&L and cross-functional accountability.

Mr. Hoffmann has worked with Eli Lilly and Company for over a 17-year period with a balance of in-country management, international regional management and headquarters global executive positions. In his various responsibilities, he established a regulatory and governmental affairs network around the world, developed in-depth commercial capabilities for all geographies including alliances, joint venture, and organic growth strategy. Mr. Hoffmann was a highly respected operational leader and presenter with continued upward momentum when recruited by Amgen, where he spent about 12-years at various leadership roles and responsibilities, including P&L accountabilities for all countries around the world including the USA.

Mr. Hoffmann has served on various board viz., Ferring Holding Inc., New Jersey, USA, Trizell Holding S.A., Lausanne, Switzerland, Shield Therapeutics PLC, Gateshead Quays, UK, EUSA Pharma, Hemel Hempstead, UK, Biotest AG, Dreieich, Germany, Trigemina, Inc., San Francisco, USA and STADA AG, Bad Vilbel, Germany. He currently serves the board of Genmab A/S, Copenhagen, Denmark, Paratek Pharmaceuticals, Inc., Boston, USA, Semdor Pharma Group GmbH, Cologne, Germany and IDT Biologika GmbH, Dessau-Rosslau, Germany.

Mr. Hoffmann has received an MBA, Kenan-Flagler Business School, UNC Chapel Hill, North Carolina, 1987, MA – English, The University of Koeln, Koeln, Germany, 1985 and MA – Kinesiology, Deutsche Sporthochschule Koeln, Koeln, Germany, 1985.

Click here to view the Directorships in Indian companies.

Dilip Shanghvi is the Founder and Executive Chairman of Sun Pharmaceutical Industries Limited. He is also the Chairman of Sun Pharma Advanced Research Company Ltd., which is engaged in R&D of new innovative drugs and delivery technologies.

He was awarded the Padma Shri in 2016 for his distinguished contribution to the Indian Trade & Industry. In January 2018, the Indian Government appointed Mr Shanghvi to the Reserve Bank of India’s 21-member central board committee. He is part of the Economic Advisory Council formed by the Government of Maharashtra to achieve rapid and comprehensive development in the state. The Government of Gujarat appointed him as the Chairman of Gujarat Biotechnology University in 2022.

Mr. Shanghvi has been conferred with many awards and recognitions. In 2023, 2021 & 2020, India’s leading magazine, India Today included him in its annual Power List of 50 influential personalities in India. Some of the other awards and recognitions bestowed on him include: Moneycontrol Lifetime Achievement Award (2023), All India Management Association (AIMA) Entrepreneur of the Year (2017), NDTV Business Leader of the Year (2015), Forbes Entrepreneur for the year (2014), Economic Times’ Business Leader of the Year (2014), CNN IBN’s Indian of the Year – Business (2011), Business India’s Businessman of the Year (2011) and Ernst and Young’s World Entrepreneur of the Year (2011). He has also been awarded the Economic Times’ Entrepreneur of the Year (2008), Business Standard’s CEO of the Year (2008) and CNBC TV 18’s First Generation Entrepreneur of the Year (2007)

He is a former President of Indian Pharmaceutical Alliance (IPA) and has also served as the chairman of the Board of Governors of Indian Institute of Technology (Bombay). He is a former trustee of the Rhodes Scholarship Program at Oxford University.

In 2019, he was conferred with an honorary doctorate by the Tel Aviv University, Israel’s largest and most comprehensive institution of higher learning.

Mr. Shanghvi has played a vital role in the globalisation of the Indian pharmaceutical industry and continues to inspire generations of entrepreneurs in their journey of success.

Click here to view the Directorships in Indian companies.

Kalyanasundaram Subramanian (‘Kal’), (born in February, 1954) joined Sun Pharmaceutical Industries Limited (‘Sun’) in January 2010 after 22 years with GSK. Kal is a Chemistry graduate and a Chartered Accountant from India with 37 years of experience. He has more than three decades of experience in the pharmaceutical industry. Mr. Kal’s career in the pharma industry began when he joined Burroughs Wellcome, in New Zealand as Commercial Advisor in 1988. In his long association with Burroughs Wellcome (which was acquired by Glaxo to become GlaxoWellcome and finally GlaxoSmithKline), he held various leadership positions, including: Vice President, Head of Classic Brands Business of Emerging Markets; Area Director South Asia & Managing Director, GSK India; Managing Director – GlaxoWellcome, Singapore (Singapore, Indochina & Myanmar) & Commercial Director – Burroughs Wellcome, New Zealand.

In 2010, Kal joined Sun as the CEO and Director: India and Emerging Markets. He was instrumental in Merck (MSD) and Sun collaboration and spearheaded the opening of Sun operations in few important markets such as Japan, MENA. In 2012, Kal moved to Taro Pharmaceutical Industries Ltd. (‘Taro’), USA, a subsidiary of Sun, to assume responsibility of Taro’s operations in North America. In January 2017, Kal moved back to India to manage India and EM regions of Sun and has was also been appointed as the CEO & whole-time Director of Sun Pharma Laboratories Limited, a wholly-owned subsidiary of Sun Pharma. He is now a Executive Director in Sun Pharma Laboratories Limited.

Mr. Makov joined Sun Pharma in 2012 and is the Chairman of the Company.

Mr. Makov is the former President & CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He led the company’s global expansion and under his leadership Teva became the undisputed global leader in the generic pharmaceutical industry and a global leader in the treatment of Multiple sclerosis.

Prior to joining Teva, Mr. Makov led a number of companies in various industries. Among them was Israel’s first biotech company, Interpharm, which he founded, and later went public in the US.

Makov is also the former Chairman of Given Imaging, the developer and world’s leading provider of capsule endoscopy, and Netafim, the pioneer and global leader in smart irrigation solutions.

Today, Mr Israel Makov is Chairman of BioLight – an emerging global ophthalmic company focused on the discovery, development and commercialization of products for ophthalmic conditions, Chairman of Nextage Therapeutics, a global pharma company that develops the next generation of cannabinoid based products, and Chairman of QuantalX NeuroScience, a clinical stage company developing Direct Electro-Physiological Imaging (DELPhI), enabling early, precise and objective evaluation of the brain’s functional status.

Mr Makov is a member of the Executive Board & Management Committee of the Weizmann Institute of Science, on the Board of Governors of the Technion, and Director at Yeda Research and Development Company Ltd. Mr. Makov is also Chairman of the Gesher Theatre, one of Israel’s leading theaters.

Mr. Makov has a B.Sc. in Agriculture and an M.Sc. in Economics from the Hebrew University in Jerusalem.

Dr. Pawan Goenka earned his B. Tech. in Mechanical Engineering from IIT, Kanpur and Ph.D. from Cornell University, U.S.A. He is also a Graduate of Advanced Management Program from Harvard Business School. He worked at General Motors R&D Centre in Detroit, U.S.A. from 1979 to 1993. Dr. Goenka joined Mahindra & Mahindra Ltd. in 1993 as General Manager (R&D) and led the development of the Scorpio SUV. Dr. Goenka is credited with building a strong R&D infrastructure, a robust product portfolio for Mahindra and is widely recognized as a statesman of the Indian Auto Industry. Dr. Goenka served on the boards of several Mahindra Group Companies, both domestic and international. He retired from Mahindra as Managing Director and CEO on 1st April 2021.

Under Dr. Pawan Goenka’s leadership, IN-SPACe has been at the forefront of implementing space reforms in India, facilitating private sector participation to boost the space economy and create a self-reliant, sustainable ecosystem. He was instrumental in shaping the Indian Space Policy 2023 and overseeing the release of Norms, Guidelines, and Procedures for its implementation. Dr. Goenka also played a key role in liberalizing the FDI policy for the space sector. Under his guidance, IN-SPACe launched the Decadal Vision and Strategy for the Indian space economy, along with an implementation roadmap aimed at increasing India’s share in the global space economy. The Strategy roadmap is being implemented through various initiatives by IN-SPACe, including fostering partnerships between Indian private space players and international agencies & foreign private players. Under Dr. Goenka’s leadership IN-SPACe is actively championing collaboration between ISRO and private players, facilitating technology transfers and handholding industry. His efforts continue to position the Indian private space sector as an emerging leader in the global space industry, attracting international interest and investment.

In addition to receiving the national honor of the Padma Shri in 2025, Dr. Goenka has received several other awards such as, Burt L. Newkirk Award, Charles L. McCuen Achievement Award, the FISITA Medal of Honour, Automotive Man of the Year Award, CV Man of the Year Award, Lifetime Achievement Award & Param Shreshth Award. Dr. Goenka was also honored with the Lifetime achievement Award for his unparalleled contribution to the automotive industry by The Automotive Component Manufacturers Association (ACMA) in March 2022.

Dr. Goenka received the Distinguished Alumni Award from IIT Kanpur in 2004 and was also conferred with the Doctor of Science (honoris causa) in 2015. He is a Fellow of SAE International and of The Indian National Academy of Engineers and a member of National Academy of Engineers, USA.

Dr. Goenka is past President of SIAM, of the Society of Automotive Engineers India, the ARAI Governing Council, and served as a Board Member of National Skills Development Corporation (NSDC) and a member of Confederation of Indian Industries (CII) National Council. He is currently serving as the Chairperson of the Board of Governors of IIT Madras and an Independent Director on the Sun Pharma Board. Dr. Goenka is the Chairperson of the Steering Committee for Advancing Local value-add and Exports (SCALE), an initiative under the Ministry of Commerce & Industry.

Rama Bijapurkar is a recognised thought leader on business-market strategy and India’s consumer economy. She has an independent management consulting practice, works across sectors, and describes her domain as bringing market focus to business strategy. She is a Professor of Management Practice at Indian Institute of Management, Ahmedabad, and co-founder of People Research on India’s Consumer Economy, a not-for-profit think tank and fact tank, on India’s economy and citizen environment for use in business strategy and public policy.

Ms. Bijapurkar is amongst India’s most experienced independent board directors and has served on the boards of several of India’s blue chip companies and public institutions.

Ms. Bijapurkar is a dominant voice in the Indian media on business and policy issues, and is the author of hallmark books on Consumer India “We are like that only: Understanding the Logic of Consumer India”, “A Never-Before World: Tracking the Evolution of Consumer India” (Penguin) and “Customer in the Boardroom – crafting customer based business strategy” (Sage)

Ms. Bijapurkar holds a BSc (Hons) degree in Physics from Delhi University and a post graduate diploma in management from the Indian Institute of Management, Ahmedabad. Her over four decades of work experience in strategy consulting and market research includes her own consulting practice, and employment with McKinsey & Company, MARG (now Nielsen India), Mode Services (now TNS India).

Click here to view the Directorships in Indian companies.

Gautam Doshi, a Chartered Accountant with a Masters degree in Commerce, has been in professional practice for over 40 years. He advises various industrial groups & families and also serves as director on the boards of public listed and unlisted companies.

Mr. Doshi has more than 40 years of experience in wide range of areas covering Mergers and Acquisitions, Direct, Indirect and International Taxation, Transfer Pricing, Accounting and Corporate and Commercial Laws. He has been actively involved in conceptualizing and implementing a number of mergers and restructuring transactions both domestic and cross border, involving many of the top 20 listed companies on the BSE as also those forming part of FTSE 100.

A prolific speaker, Mr Doshi has addressed several seminars and conferences within and outside of India, and courses organized by the Institute of Chartered Accountants of India, International Fiscal Association, other professional bodies and Chambers of Commerce. He has served on the Councils of Western Region as also All India level of the Institute of Chartered Accountants of India which has the task of development and regulation of profession of accountancy in India. During his tenure on the Council, he served on several committees and contributed significantly to the work of Board of Studies which is responsible for education and system of training of students. He also served as Chairman of Committees on direct and indirect taxation.

Click here to view the Directorships in Indian companies.

A graduate of The Wharton School, University of Pennsylvania, Vidhi Shanghvi currently leads Sun Pharma’s Consumer Healthcare Business and India Distribution. With over 13 years of diverse experience, she has held leadership roles across Marketing, Brand Building, Project and Alliance Management, and Distribution.

Vidhi began her career at Sun Pharma in 2012 as a Brand Manager within the India Business. In 2014, she was appointed Marketing Head for one of the Business Units within the Cardiovascular Division Cluster. During her tenure, she spearheaded key improvements in business processes and drove digital transformation initiatives that enhanced operational efficiency.

Following the merger of Ranbaxy with Sun Pharma in 2015, Vidhi took charge as Business Head of Sun Pharma’s Consumer Healthcare Business. Under her leadership, the business has experienced substantial growth. With a portfolio of flagship brands including Revital H and Volini, she has played a pivotal role in expanding distribution reach across pharmacies, retail stores and online e-commerce platforms in India. Along with her responsibilities in the Consumer Healthcare Business, Vidhi has been leading India Distribution, a critical component of Sun Pharma’s domestic value chain.

Click here to view the Directorships in Indian companies.

Ms. Satyavati Berera is the former Chief Operating Officer (COO) of PwC India. After 40+ years of managing diverse portfolios and playing key leadership roles, Ms. Berera retired from the firm in 2023. Ms. Berera is an Economics Graduate from Lady Shri Ram College, Delhi University and a fellow member of the Institute of Chartered Accountants of India (ICAI).

Ms. Berera qualified as a Chartered Accountant in 1984 and subsequently became a Partner in 1995 with Price Waterhouse. Before becoming the COO in 2016, Ms. Berera headed the consulting practice and was also the Managing Partner for the firm’s, northern region. Ms. Berera served as an Audit Partner from 1995 to 2005.

Ms. Berera has extensively worked across industry sectors in the areas of Assurance, Consulting and Governance Risk and Compliance services (GRC). Ms. Berera was actively involved in designing and implementing control strengthening and process improvement solutions for a variety of domestic and multinational Companies.

Ms. Berera’s role as the COO, has given her a deep understanding of Finance, Operations, Human Capital, Technology & Risk and Regulatory & Compliance environment.

Click here to view the Directorships in Indian companies.

Dr. Andreas Eugen Busch, PhD, has led R&D organizations in big pharma and biotech organizations. Most recently he served as Chief Innovation officer at Absci, and prior to that he led R&D at Bayer and Shire. Dr. Busch brings substantial drug hunting expertise to Sun Pharmaceutical’s Board. His leadership has resulted in over 15 commercial drugs starting from bench to FDA approval with several more in late-stage clinical development. He received numerous scientific awards and holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany, where he also received his PhD in Pharmacology.

Click here to view the Directorships in Indian companies.